DoD Arthritis, Focused Research Award | HT942524ATRPFRA

Opportunity Information: Apply for HT942524ATRPFRA

The FY24 Department of Defense (DoD) Arthritis, Focused Research Award (FRA) is a discretionary grant opportunity run through the Congressionally Directed Medical Research Programs (CDMRP) and administered by the U.S. Army Medical Research Acquisition Activity (USAMRAA). Its purpose is to fund conceptually innovative, high-risk/potentially high-reward research that could open new directions in arthritis science and, over time, translate into meaningful improvements in patient care or quality of life. The program is broadly inclusive of arthritis conditions, encouraging proposals across osteoarthritis, post-traumatic arthritis, inflammatory arthritis, juvenile arthritis, rheumatoid arthritis, and other understudied or less commonly researched forms.

A central requirement is that applicants clearly explain how their work could eventually reduce the burden of arthritis and lead to downstream benefits for patients. The DoD emphasis is not just on scientific novelty, but on why the expected outcomes matter for real-world health and function, particularly in military-relevant contexts. Proposals are expected to articulate how arthritis affects Service Members, their Families, and Veterans, and how the proposed research could contribute to better readiness, recruitment, retention, rehabilitation, and recovery. Applicants can also describe potential impacts within the Military Health System, including considerations relevant to TRICARE-supported care, but the key point is demonstrating a plausible pathway from the research to improved care practices or quality-of-life outcomes.

To fit this mechanism, the project must address at least one of the FY24 FRA focus areas (the specific list is referenced in the announcement and must be matched explicitly in the application). Within that framework, the program encourages applicants to strengthen impact by leveraging large data sets, existing studies, or established research consortia when appropriate, especially if doing so increases statistical power, generalizability, or the speed at which findings can be validated and built upon.

The award is offered in two distinct Research Levels, and an application must choose only one level. Research Level 1 is designed for exploratory, early-stage ideas that are genuinely high-risk but could be high-reward, such as proposing a new approach, tool, model, or paradigm that creates new avenues for investigation. Early career investigators are especially encouraged at this level. Research Level 2 is intended for projects that are more advanced on the preclinical path and are aimed at moving findings toward clinical translation. Level 2 requires preliminary and/or published data (the data can come from the applicant team or be drawn from other sources) and should be anchored by a strong scientific rationale and a clear, testable hypothesis supported by a careful analysis of the literature.

Across both levels, the CDMRP places heavy weight on rigor and reproducibility in experimental design and reporting. Applicants are expected to incorporate best practices such as randomization, blinding where feasible, appropriate sample-size estimation, and transparent data handling, reflecting standards like those discussed in Landis et al. (Nature, 2012) on improving the predictive value of preclinical research. In addition, the program encourages applicants to address sex as a biological variable and to consider questions tied to women’s health, especially where arthritis affects women uniquely, disproportionately, or differently from men. Strong applications typically do more than mention sex differences; they build sex-aware reasoning into the research design, analysis plan, and interpretation of outcomes.

A major boundary of this funding mechanism is that it is intended for preclinical and/or animal research and cannot be used for clinical research or clinical trials. The announcement distinguishes clinical trials (prospective assignment of human subjects to interventions to evaluate biomedical or behavioral outcomes under 45 CFR 46.102) from broader clinical research, which includes observational work involving identifiable human data/specimens or interaction with human subjects, as well as epidemiologic, behavioral, outcomes, and health services research that does not test intervention efficacy. Applicants with human-subjects clinical research or trials are directed instead to the separate FY24 ATRP Clinical Research Award opportunity.

From a funding and administrative standpoint, awards are made as grants under 31 USC 6304. The total budget cap for the entire period of performance is up to $500,000 for Research Level 1 and up to $750,000 for Research Level 2. The DoD expects to allocate roughly $2.5 million in total, supporting an estimated four awards overall (approximately two at each research level), though actual funding depends on federal funds availability, the number of submissions, and how proposals score in peer and programmatic review. The opportunity is listed as unrestricted eligibility, meaning a wide range of applicant organizations can generally apply. The opportunity number is HT942524ATRPFRA, the CFDA number is 12.420, and the original application deadline is October 30, 2024. Awards using FY24 funds are expected to be made no later than September 30, 2025, and FY24 funds associated with these awards are anticipated to remain available for use until they expire on September 30, 2030.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Arthritis, Focused Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-08-16.
• Applicants must submit their applications by 2024-10-30. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524ATRPFRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: